• Recruiting

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma

Updated: May 24

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma

TriPRIL

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells.


This research study involves the study drugs:.

TriPRIL CAR T Cells

Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process


Massachusetts General Hospital

 

ClinicalTrials.gov Identifier: NCT05020444


Official Title: A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma


First Posted: August 25, 2021


Click here for details on ClinicalTrials.gov

 

Drug: TriPRIL CAR T Cells

Drug: Cyclophosphamide

Drug: Fludarabine

 

TriPRIL CAR T Cells


Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells (Code C183542)

Autologous Anti-BCMA/Anti-TACI Trimeric APRIL-based CAR T-cells

Autologous Anti-BCMA/TACI Trimeric APRIL-based CAR-T Cells

Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells

TriPRIL CAR T Cells

 

Location

United States, Massachusetts







Posts Archive